Purpose
We found higher peritonitis rates in patients receiving Gambrosol Trio® and wished to describe this finding further.

Methods
Secondary analysis of peritonitis events in a single-blind controlled trial involving 99 patients in two centers in Toronto and one in Hong Kong assessing the effects of Gambrosol Trio® relative to standard peritoneal dialysis solutions (Baxter products) on residual renal function. Statistical analysis: Between-group proportions of patients with peritonitis were adjusted using the Bonferroni correction for multiple testing. Fischer’s exact test was used to compare frequencies of peritonitis episodes between groups.

Results
Peritonitis episodes: Fifty patients were randomized to receive Gambrosol Trio® and 49 to receive standard solution. There were 53 episodes of peritonitis in 27 patients treated with Gambrosol Trio® and 22 episodes in 15 patients receiving standard solutions. There was no significant between-group difference in the proportion of patients with peritonitis (0.54 vs 0.31, p>0.05) or number of episodes per patient with peritonitis (1.96 vs 1.47, p=0.3012).

Conclusion
Compared to those receiving standard PD solutions, patients receiving Gambrosol Trio® solutions experienced a non-significant increase in the incidence of peritonitis episodes. This effect was seen across the three participating centres. More infections from gram-negative organisms were observed in the Gambrosol Trio® arm, and more gram-positive infections were seen in the standard solution arm.